Abstract
Current genetic tests for rare diseases provide a diagnosis in only a modest proportion of cases. The Full Genome Analysis method, FGA, combines long-range assembly and whole-genome sequencing to detect small variants, structural variants with breakpoint resolution, and phasing. We built a variant prioritization pipeline and tested FGA’s utility for diagnosis of rare diseases in a clinical setting. FGA identified structural variants and small variants with an overall diagnostic yield of 40% (20 of 50 cases) and 35% in exome-negative cases (8 of 23 cases), 4 of these were structural variants. FGA detected and mapped structural variants that are missed by short reads, including non-coding duplication, and phased variants across long distances of more than 180kb. With the prioritization algorithm, longer DNA technologies could replace multiple tests for monogenic disorders and expand the range of variants detected. Our study suggests that genomes produced from technologies like FGA can improve variant detection and provide higher resolution genome maps for future application.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funded by the California Initiative to Advance Precision Medicine to D.M. the Marcus Program in Precision Medicine and Established Investigator Grants to J.T.S. and P-Y.K., and the National Human Genome Research Institute of the National Institutes of Health under award R01 HG005946 to P-Y.K. The National Science Foundation Graduate Research Fellowship under Grant No. DGE 1752814 support for A.G.S. We thank the families for their participation. We thank the California Initiative to Advance Precision Medicine and the California Governors Precision Medicine Advisory Committee.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Institutional review board of Childrens Hospital Oakland and University of California, San Francisco (UCSF), Committee for Human Subjects Research. Recruitment was from UCSF Benioff Childrens Hospital Medical Genetics and Genomics clinics. We focused on cases of two types, chosen to demonstrate the capability of FGA: cases in which whole-exome sequencing had not returned a causal variant; sporadic cases from the pediatric population that are suspected to have a genetic basis, but fall into no clear syndrome and have no clear candidate target for conventional genetic diagnosis. Individuals with undiagnosed conditions and unaffected parents were offered testing and underwent an informed consent process prior to blood draw. The nature and possible risks of the study were explained in the consent process. Phenotypic evaluation was performed by clinical review by at least two genetics professionals, and human phenotype ontology terms were curated for each case.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Sequence libraries available upon request.
